Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

TARGETING RECEPTOR TYROSINE KINASE ON ENDOTHELIAL CELLS IN AN ORTHOTOPIC TUMOR MODEL OF ORAL SQUAMOUS CELL CARCINORMA

구강 편평상피세포암 동위종양 모델에서 내피세포의 수용체 타이로신 인산화효소에 대한 표적치료

  • Park, Young-Wook (Department of Oral & Maxillofacial Surgery, College of Dentistry, Kangnungwonju National University) ;
  • Kim, So-Hee (Department of Pharmacology, College of Dentistry, Kangnungwonju National University)
  • 박영욱 (강릉원주대학교 치과대학 구강악안면외과학교실) ;
  • 김소희 (강릉원주대학교 치과대학 약리학교실)
  • Published : 2009.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We determined the therapeutic effects of blockade of epidermal growth factor(EGF) and vascular endothelial growth factor(VEGF) receptor tyrosine kinases on the growth of oral squamous cell carcinoma(OSCC) xenografted in athymic nude mice. Experimental Design: We investigated the in vivo antitumor effects of a tyrosine kinase inhibitor for EGFR and VEGFR-2, AEE788 in a mouth floor(orthotopic) tumor model. Nude mice with orthotopic tumors were randomized to receive AEE788, paclitaxel, a combination of AEE788 and paclitaxel, or control. Antitumor mechanisms of AEE788 were determined by immunohistochemical/immunofluorescent and apoptosis assays. Results: Tumors of mice treated with AEE788 demonstrated down-regulation of phosphorylated EGFR, phosphorylated VEGFR and their downstream mediators(pMAPK and pAkt), decreased proliferative index, decreased microvessel density(MVD). As a result, growth of the primary tumor and nodal metastatic potentials were inhibited by AEE788. Conclusion: These data show that EGFR and VEGFR can be molecular targets for the treatment of OSCC.

Keywords

References

  1. Kupferman ME, Myers JN: Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol Clin North Am 2006 ; 39(2): 229-247 https://doi.org/10.1016/j.otc.2005.11.003
  2. Choi S, Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008; 87(1): 14-32 https://doi.org/10.1177/154405910808700104
  3. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 2007; 12(5): 327-340 https://doi.org/10.1007/s10147-007-0699-1
  4. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D et al: AEE788 : A dual family epidermal growth factor receptor/ ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941 https://doi.org/10.1158/0008-5472.CAN-03-3681
  5. Lopez-Albaitero A, Ferris RL: Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007; 133(12): 1277-1281 https://doi.org/10.1001/archotol.133.12.1277
  6. Park YW, Lee JW, Kim SH: Expressions of metastasis-related factors in orthotopic tumor models of oral squamous cell carcinoma. J Kor Assoc Maxillofac Plast Reconstr Surgeons 2008; 30(6): 529-539
  7. Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, Bucana CD et al: AEE788, a dual tyrosine kinase inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 2005; 11: 1963-1973 https://doi.org/10.1158/1078-0432.CCR-04-1665
  8. Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD et al : Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64: 7977-7984 https://doi.org/10.1158/0008-5472.CAN-04-1477
  9. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS et al : Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation. Cancer Res 2005; 65: 4716-4727 https://doi.org/10.1158/0008-5472.CAN-04-4196
  10. Schiff BA, Mcmurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG et al: Epidermal frowth factor receptor(EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin cancer res 2004; 10(24): 8594-602 https://doi.org/10.1158/1078-0432.CCR-04-0690
  11. Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fans D, Villares GJ et al: Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 2008; 10(5): 489-500 https://doi.org/10.1593/neo.08200
  12. Sano D, Myers JN: Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007; 26: 645-662 https://doi.org/10.1007/s10555-007-9082-y
  13. Park YW: Targeted molecular therapy in a murine model of oral squamous cell carcinoma with an epidermal growth factor receptor inhibitor. J Kor Assoc Maxillofac Plast Reconstr Surgeons 2009; 31(1): 8-17
  14. Yazici S, Kim SJ, Busby JE, He J, Thaker PH, Yokoi K et al: Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 2005; 65(3): 203-215 https://doi.org/10.1002/pros.20283
  15. Yokoi K, Kim SJ, Thaker P, Yazici S, Man DH, He J et al: Induction of apoptosis on tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia 2005; 7(7): 696-704 https://doi.org/10.1593/neo.05193
  16. Yu C, Friday BB, Lai JP, Mccollum A, Atadja P, Roberts LR et al: Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin cancer res 2007; 13(4): 1140-1148 https://doi.org/10.1158/1078-0432.CCR-06-1751
  17. Sasaki T, Kitadai Y, Nakamura T, Kim JS, Tsan RZ, Kuwai T et al: Inhibition if epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia 2007; 9(12): 1066-1077 https://doi.org/10.1593/neo.07667
  18. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P et al: Expression of the epidermal growth factor receptor( EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast cnacer research 2008; 10(3): 1-8 https://doi.org/10.1186/bcr1999
  19. Verheul HMW, Hammers H, Erp KV, Wei Y, Sanni T, Salumbides B et al: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin cancer res 2007; 13(14): 4201-4208 https://doi.org/10.1158/1078-0432.CCR-06-2553
  20. Roberts N, Kloos B, Cassella M, Podgrabinska S, persuad K, Wu Y et al: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer res 2006; 66(5): 2650-2657 https://doi.org/10.1158/0008-5472.CAN-05-1843
  21. Laakkonen P, Waltari M, Holopainen T, Takahashi T, pytowski B, Steiner P et al: Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer res 2007; 67(2): 593-599 https://doi.org/10.1158/0008-5472.CAN-06-3567
  22. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S et al: Vascular endothelial growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005; 65(11): 4739-4746 https://doi.org/10.1158/0008-5472.CAN-04-4576
  23. Dumont DJ, Jussila L, Taipale J: Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-949 https://doi.org/10.1126/science.282.5390.946
  24. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J et al: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer res 2005; 65(9); 3716- 3725 https://doi.org/10.1158/0008-5472.CAN-04-3700
  25. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ: Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 2006; 8(9): 747-757 https://doi.org/10.1593/neo.06322
  26. Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K et al: Immunohistochimistry for the evaluation of angiogenesis in tumor xenografts. Biotech Histochem 2008; 83(3): 179-189 https://doi.org/10.1080/10520290802451085